Jason thanks for your blog and stretched me greatly to think differently.

I really liked the 'resiliency-monitoring tool' for resources close to nature. Finance as a tool is evolving, amending methodology where gaps exist. It seems even more essential now to develop sustainable valuation tools.

As to your example of pricing for prescription drugs and side effects - I'd rather see a sort of ROI that is adjusted FOR the side-effects - similar to the Sharp ratio = Expected outcome of the drug / std dev of side effects.